Search hospitals > Tennessee > Nashville
Tennessee Oncology PLLC
Claim this profileNashville, Tennessee 37203
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Tumors
Conducts research for Cancer
Conducts research for Lung Cancer
296 reported clinical trials
11 medical researchers
Summary
Tennessee Oncology PLLC is a medical facility located in Nashville, Tennessee. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Tumors, Cancer, Lung Cancer and other specialties. Tennessee Oncology PLLC is involved with conducting 296 clinical trials across 156 conditions. There are 11 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
HER2 negative
Top PIs
Melissa Johnson, MDSarah Cannon Research Institute5 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
62 reported clinical trials
89 drugs studied
Erika P HamiltonSarah Cannon Research Institute4 years of reported clinical research
Expert in Breast Cancer
Expert in Ovarian Cancer
53 reported clinical trials
76 drugs studied
Meredith A McKeanSarah Cannon Research Institute1 year of reported clinical research
Expert in Solid Tumors
Expert in Tumors
34 reported clinical trials
66 drugs studied
David R. Spigel, MDTennessee Oncology3 years of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Tumors
29 reported clinical trials
54 drugs studied
Clinical Trials running at Tennessee Oncology PLLC
Breast Cancer
Tumors
Solid Tumors
Non-Small Cell Lung Cancer
Lymphoma
Cancer
Follicular Lymphoma
Non-Hodgkin's Lymphoma
Ovarian Cancer
Brain Tumor
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
ARV-471
for Breast Cancer
This trial tests a new oral medicine, ARV-471, against an existing injectable treatment, fulvestrant, in people with advanced breast cancer that has spread. Both medicines aim to slow cancer growth by targeting estrogen receptors. ARV-471 is developed as an oral alternative to fulvestrant.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Tennessee Oncology PLLC?
Tennessee Oncology PLLC is a medical facility located in Nashville, Tennessee. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Tumors, Cancer, Lung Cancer and other specialties. Tennessee Oncology PLLC is involved with conducting 296 clinical trials across 156 conditions. There are 11 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.